The closing price of CryoPort Inc (NASDAQ: CYRX) was $16.52 for the day, up 3.06% from the previous closing price of $16.03. In other words, the price has increased by $+0.49 from its previous closing price. On the day, 792668 shares were traded.
Ratios:
Our analysis of CYRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 11.16 and its Current Ratio is at 11.73. In the meantime, Its Debt-to-Equity ratio is 0.85 whereas as Long-Term Debt/Eq ratio is at 0.84.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 13, 2024, Reiterated its Buy rating but revised its target price to $18 from $19 previously.
On August 17, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $16.
Stephens Downgraded its Overweight to Equal-Weight on August 10, 2023, while the target price for the stock was maintained at $15.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 15 ’24 when SHELTON JERRELL sold 57,039 shares for $15.30 per share. The transaction valued at 872,884 led to the insider holds 634,352 shares of the business.
Mandalam Ramkumar sold 3,217 shares of CYRX for $47,226 on Mar 15 ’24. The Director now owns 43,187 shares after completing the transaction at $14.68 per share. On Mar 15 ’24, another insider, Sawicki Mark W, who serves as the Chief Scientific Officer of the company, sold 1,312 shares for $15.43 each. As a result, the insider received 20,247 and left with 73,061 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYRX now has a Market Capitalization of 785.60M and an Enterprise Value of 771.12M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.47 while its Price-to-Book (P/B) ratio in mrq is 1.75. Its current Enterprise Value per Revenue stands at 3.31 whereas that against EBITDA is -11.62.
Stock Price History:
Over the past 52 weeks, CYRX has reached a high of $24.30, while it has fallen to a 52-week low of $9.00. The 50-Day Moving Average of the stock is 15.69, while the 200-Day Moving Average is calculated to be 14.94.
Shares Statistics:
CYRX traded an average of 423.98K shares per day over the past three months and 717.97k shares per day over the past ten days. A total of 48.97M shares are outstanding, with a floating share count of 47.46M. Insiders hold about 3.10% of the company’s shares, while institutions hold 103.73% stake in the company. Shares short for CYRX as of Feb 29, 2024 were 3.91M with a Short Ratio of 9.23, compared to 4.3M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.99% and a Short% of Float of 9.62%.
Earnings Estimates
The firm’s stock currently is rated by 9 analysts. On average, analysts expect EPS of -$0.35 for the current quarter, with a high estimate of -$0.19 and a low estimate of -$0.42, while EPS last year was -$0.16. The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.15 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$0.58 and -$1.62 for the fiscal current year, implying an average EPS of -$1.3. EPS for the following year is -$0.95, with 8 analysts recommending between $0.13 and -$1.4.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $61.09M to a low estimate of $56.6M. As of the current estimate, CryoPort Inc’s year-ago sales were $62.82M, an estimated decrease of -6.50% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $60.29M, an increase of 1.60% over than the figure of -$6.50% in the same quarter last year. There is a high estimate of $61.98M for the next quarter, whereas the lowest estimate is $57.4M.
A total of 9 analysts have provided revenue estimates for CYRX’s current fiscal year. The highest revenue estimate was $248.36M, while the lowest revenue estimate was $242.6M, resulting in an average revenue estimate of $245.68M. In the same quarter a year ago, actual revenue was $233.25M, up 5.30% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $272.21M in the next fiscal year. The high estimate is $283.37M and the low estimate is $263.93M. The average revenue growth estimate for next year is up 10.80% from the average revenue estimate for this year.
